The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index; 9 of the 20 sources its claims cite were checked for support.
Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial
Open accessAbstract
RATIONALE: Deupirfenidone is a strategically deuterated form of pirfenidone that retains pharmacodynamic activity but has a differentiated pharmacokinetic profile that may enable improved efficacy and favorable tolerability in patients with idiopathic pulmonary fibrosis (IPF). OBJECTIVES: To evaluate the efficacy and safety of deupirfenidone compared with placebo and pirfenidone in patients with IPF. METHODS: Patients were randomized 1:1:1:1 to deupirfenidone 550 mg TID, deupirfenidone 825 mg TID, pirfenidone 801 mg TID, or placebo. The primary endpoint was the rate of change in forced vital capacity (FVC) for the combined arms of deupirfenidone versus placebo at 26 weeks. The primary and secondary analyses used Bayesian and frequentist approaches, respectively. MEASUREMENTS AND MAIN RESULTS: A total of 257 patients with IPF were randomized, and the proportion on treatment at the end of the study was 80.0%, 68.3%, 64.6%, and 78.1% for the placebo, pirfenidone, deupirfenidone 550 mg, and deupirfenidone 825 mg arms, respectively. Posterior mean change in FVC for placebo was -110.71 mL (95% credible interval (CI), -148.75, -70.98), and for the combined deupirfenidone arms was -48.42 mL (95% CI, -87.66, -9.04) with a posterior mean difference of 62.29 mL (95% CI l, -6.13, 115.73; posterior probability, 0.985). Using a frequentist approach, the adjusted mean change in FVC for the placebo arm was -112.5 mL (95% CI, -167.2, -57.8), and for the deupirfenidone 825 mg arm was -21.5 mL (95% CI, -78.2, 35.1); the adjusted mean difference was 91.0 mL (95% CI, 12.2, 169.7; P = .02). The most common adverse events for each active treatment arm were gastrointestinal. CONCLUSIONS: In patients with IPF, treatment with deupirfenidone slowed lung disease progression over 26 weeks. TRIAL REGISTRATION: Clinicaltrials.gov number NCT05321420.
Overview
CoChat Summary
## TL;DR
ELEVATE-IPF was a 4-arm phase 2b randomized, double-blind trial in IPF that compared two doses of deupirfenidone with pirfenidone and placebo over 26 weeks. Deupirfenidone 825 mg TID slowed FVC decline versus placebo and had a safety profile similar to pirfenidone, but the study was not powered to prove superiority over pirfenidone.
## Key findings
- 257 patients with IPF were randomized; 80.0% on placebo, 68.3% on pirfenidone, 64.6% on deupirfenidone 550 mg, and 78.1% on deupirfenidone 825 mg remained on treatment at week 26.
- In the Bayesian primary analysis, pooled deupirfenidone reduced the 26-week decline in FVC versus placebo: -48.42 mL vs -110.71 mL, with a posterior mean difference of 62.29 mL and posterior probability of superiority of 0.985.
- In the frequentist analysis, deupirfenidone 825 mg TID improved FVC decline versus placebo by 91.0 mL (95% CI 12.2, 169.7; P = .02); FVC percent predicted also improved by 3.00 (95% CI 0.62, 5.38; P = .01).
- Time to IPF progression (>5% decline in FVCpp over 26 weeks or death) was delayed with deupirfenidone 825 mg TID vs placebo (HR 0.439, 95% CI 0.255, 0.756; P = .0023).
- The most common adverse events were gastrointestinal, and grade 3 or higher TEAEs were uncommon; the paper reports 13.8% placebo, 15.9% pirfenidone, 20.0% deupirfenidone 550 mg, and 12.5% deupirfenidone 825 mg.
## Methods
- 4-arm, randomized, double-blind, active- and placebo-controlled, dose-finding phase 2b trial across 87 sites in 14 countries.
- Patients with IPF aged ≥40 years were randomized 1:1:1:1 to deupirfenidone 550 mg TID, deupirfenidone 825 mg TID, pirfenidone 801 mg TID, or placebo; 257 patients received at least one dose.
- Primary endpoint was rate of decline in FVC over 26 weeks; the primary analysis used a Bayesian linear mixed-effects model with dynamic borrowing from historical placebo data, and secondary analyses used frequentist mixed models. Time-to-event outcomes used Kaplan-Meier, log-rank, and Cox regression.
## Limitations
- The paper states the overall sample size and 26-week duration were inadequate to understand effects on secondary endpoints including hospitalizations, survival, and quality of life.
- The study was not powered to demonstrate superiority of deupirfenidone over pirfenidone.
- Patients with prior pirfenidone exposure were excluded and background nintedanib was not permitted, which may limit generalizability; this is stated in the paper.
- Evident from the text: missing 26-week data, especially in the pirfenidone arm due to deaths, may have affected analyses; the paper says this “may have impacted analyses.”
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
7 Valid · 2 Not valid · 3 Not checked · 60 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Background nintedanib was not allowed because previous small clinical trials assessing the combination of nintedanib and pirfenidone have shown high rates of adverse events and discontinuation that could have compromised study integrity.17,18”
§ Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial > Discussion
What the sources say
- Not checked — no full text of the sourcecites [17] Vancheri, 2018, Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial, Am J Respir Crit Care Med source
- Partly supportedcites [18] Flaherty, 2018, Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis, Eur Respir J sourceExperimental — accuracy not yet measured
The Results report adverse events in 88 of 89 patients and discontinuation due to adverse events in 13 patients (15%). But the Discussion concludes that most patients tolerated the combination and that discontinuation rates were similar to those expected with either drug alone. The paper does not say these rates threatened another study’s integrity or explain a decision to prohibit background nintedanib. Page numbers were not provided in our copy. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The Bayesian approach incorporated dynamic borrowing of historical placebo data from several external IPF trials, including the ASCEND, INPULSIS, and TOMORROW studies (Figures E2 and E3).2,3,13”
§ Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial > Methods > Statistical analyses
What the sources say
- Not checked — no full text of the sourcecites [2] King, 2014, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med source
- Supportedcites [3] Richeldi, 2014, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, N Engl J Med source
The Methods passage in our copy identifies this paper as reporting the INPULSIS-1 and INPULSIS-2 trials. In the citing sentence, this source serves to identify an INPULSIS trial used as historical data; the Bayesian borrowing approach is the citing authors’ analysis, not a method attributed to this trial report. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [13] Richeldi, 2011, Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All-cause mortality during the treatment period was lower in both deupirfenidone arms (1 patient (1.6%) in the 825 mg arm and 1 patient (1.6%) in the 550 mg arm) compared to pirfenidone (5 patients; 7.9%) and placebo (2 patients; 3.2%).”
§ Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial > Results > Safety
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cough, dyspnea, and worsening of IPF generally occurred more frequently with placebo.”
§ Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial > Results > Safety
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The posterior mean change in absolute FVC from baseline to week 26 using Bayesian analysis for placebo was -110.71 mL (95% credible interval, -148.75, -70.98)”
§ Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial > Results > Efficacy
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
36 more claims
Create a free account to see all 72 claims and every source verdict.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 13
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Graham, B. L., Steenbruggen, I., Miller, M. R., Barjaktarevic, I. Z., Cooper, B. G., Hall, G. L., Hallstrand, T. S., Kaminsky, D. A., McCarthy, K., McCormack, M. C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1590st · Cited by 4,305
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Deuterium in drug discovery: progress, opportunities and challenges
Di Martino, R. M. C., Maxwell, B. D., & Pirali, T. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00703-8 · Cited by 539
Antifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454
Nathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I., Glassberg, M. K., Kardatzke, D. R., Daigl, M., Kirchgaessler, K.-U., Lancaster, L. H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30326-5 · Cited by 335
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1301oc · Cited by 305
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201737 · Cited by 236
Self-citation
Cited by
Newton, C. A. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag237
Reply to Sun et al.: Interpreting benefit in ELEVATE-IPF
Maher, T. M., Hamblin, M. J., Graham, C. S., & Kulkarni, T. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag283
Self-citationInterpreting benefit in ELEVATE-IPF
Sun, M., Zang, D., & Chen, J. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag282
Metadata
- Authors
- Maher, T. M., Hamblin, M. J., Choi, W.-I., Case, A. H., Tomos, I. P., Tzouvelekis, A. E., Shore, J. E., Bergna, M. A., Golod, D., Elenko, E., Zhang, Y., Graham, C. S., Song, J. W., Kulkarni, T., and the ELEVATE IPF Investigators, Maillo, M., Bergna, M., Rojas, R. A., Wehbe, L., Cazaux, A., Chirino, A., Elias, P. C., Molinari, L., Molina, A., Fazio, C., Kohn, V., Arce, G., Raso, E., Florenzano, M., Miranda, G., Gallegos, J. P., Orellana, A. R. S., Cano, D., Castano, T. V., Tchkonia, D., Vacharadze, K., Katsarava, V., Gonjilashvili, N., Kupreishvili, L., Antoniou, K., Manika, A., Tzouvelekis, A., Tomos, I., Manali, E., Deb, J., Katiyar, S., Nath, A. R., Deshmukh, H., Kakkad, T., Swarnakar, R., Udachankar, G., Deshmukh, A., Aflah, S. S. S., Pang, Y.-K., Muhammad, N. A., Razak, M. R. A., Ali, I. A. H., Hing, C. T. A., Colli, A., Moreno, J. F., Llamas, F. S., Valay, R. P., Garcia, C. H., Santiaguel, J., Campomanes, M., Dionisio, P. J., Oancea, C., Davidescu, L., Cojocaru, C., Dawood, R. S., Kalla, I., Mey, L., Van Der Linden, M., Williams, P. G., Song, J. W., Kim, Y. H., Yoon, H. K., Kim, E. K., Choi, H. S., Park, S. H., Yoo, H., Choi, W.-I., Lee, Y., Jegal, Y., Jeong, S. H., Shin, H.-J., Park, D., Lee, J. H., Park, J. H., Bangpattanasiri, K., Ratanawatkul, P., Teerapuncharoen, K., Jensen, T. P., Wendelberger, B., Khandwala, F., McGlothlin, A., Milstone, A., Singla, A., Fernandez, J., Hamblin, M., Kulkarni, T., Lupercio, R., Bregman, B., Parisi, R., Mageto, Y., Patel, D., Maher, T., Stringer, W., Siddiqi, A., Johri, S., Criner, G., Rankin, B., Puppala, R., Case, A., Klein, R., Ramaswamy, M., Lancaster, L., Astor, T., & Rasheed, A.
- Affiliations
- Imperial College, National Heart and Lung Institute , London,
- University of Kansas Medical Center (US)
- Piedmont Atlanta Hospital (US)
- Sotiria General Hospital (GR)
- Department of Respiratory Medicine, University of Patras , Patras,
- Pulmonary Fibrosis Foundation (US)
- Department of Research, CEMER, Florida , Vicente López,
- PureTech (United States) (US)
- ORCID
- Case, Amy Hajari
- Tomos, Ioannis P
- Graham, Camilla S
- Cazaux, Alexis
- Fazio, Cristian
- Kohn, Victoria
- Tomos, Ioannis
- Swarnakar, Rajesh
- Santiaguel, Joel
- Davidescu, Lavinia
- Cojocaru, Cristian
- Kalla, Ismail
- Yoon, Hyoung Kyu
- Kim, Eun Kyung
- Choi, Hye Sook
- Park, Sun Hyo
- Yoo, Hongseok
- Jegal, Yangjin
- Jeong, Sung Hwan
- Shin, Hong-Joon
- Park, DongWon
- Park, Joo Hun
- Ratanawatkul, Pailin
- Teerapuncharoen, Krittika
- Wendelberger, Barbara
- Mageto, Yolanda
- Johri, Shilpa
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2026-04-02
- Volume
- 212
- Issue
- 8
- Pages
- 1761-1769
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC13424664
- OpenAlex
- W7148454282
- Cited by
- 4
- References
- 19
- Citations by year
- 2026: 4
- FWCI
- 18.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- PureTech Health
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, deuterated drugs, forced vital capacity, lung function decline, antifibrotic therapy, pharmacokinetics, drug safety, treatment tolerability, Bayesian analysis, frequentist analysis, dose comparison, medication adherence, treatment discontinuation
- MeSH terms
- Aged, Anti-Inflammatory Agents, Non-Steroidal, Double-Blind Method, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial. https://app.cochat.ai/papers/10.1093/ajrccm/aamag155
- The paper
- Maher, T. M., Hamblin, M. J., Choi, W.-I., Case, A. H., Tomos, I. P., Tzouvelekis, A. E., Shore, J. E., Bergna, M. A., Golod, D., Elenko, E., Zhang, Y., Graham, C. S., Song, J. W., Kulkarni, T., and the ELEVATE IPF Investigators, Maillo, M., Bergna, M., Rojas, R. A., Wehbe, L., . . . Rasheed, A. (2026). Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1093/ajrccm/aamag155
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.